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Background
In May 2021, the Scientific Advisory Committee on Nutrition (SACN) published a risk assessment on lower carbohydrate diets for adults with type 2
diabetes (T2D)(1). The purpose of the reportwas to review the evidence on ‘low’-carbohydrate diets comparedwith the current UKgovernment advice
on carbohydrate intake for adults with T2D. However, since there is no agreed andwidely utilised definition of a ‘low’-carbohydrate diet, comparisons
in the report were between lower and higher carbohydrate diets. SACN’s remit is to assess the risks and benefits of nutrients, dietary patterns, food
or food components for health by evaluating scientific evidence and to make dietary recommendations for the UK based on its assessment(2). SACN
has a public health focus and only considers evidence in healthy populations unless specifically requested to do otherwise. Since the Committee
does not usually make recommendations relating to clinical conditions, a joint working group (WG) was established in 2017 to consider this issue.
The WG comprised members of SACN and members nominated by Diabetes UK, the British Dietetic Association, Royal College of Physicians
and Royal College of General Practitioners. Representatives from NHS England and NHS Health Improvement, the National Institute for Health
and Care Excellence and devolved health departments were also invited to observe theWG. TheWGwas jointly chaired by SACN and Diabetes UK.
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The terms of reference for the working group were to review the
evidence on lower carbohydrate diets (alongside higher fat and/
or higher protein) comparedwith the current government advice
for adults with type 2 diabetes (T2D); consider the impact, in
adults with T2D, of lower compared with higher carbohydrate
diets on markers and clinical outcomes of T2D including any
potential adverse effects and make recommendations based
on the review of the evidence. Its remit did not include consid-
eration of the wider management of T2D, studies of children,
peoplewith pre-diabetes, type 1 diabetes or gestational diabetes.
Diabetes
Diabetes is a condition in which the body does not produce suf-
ficient insulin to regulate blood glucose levels and the insulin
produced does not work effectively. This leads to elevated blood
glucose concentrations (hyperglycaemia) which causes damage
to blood vessels and nerves.
There are two main types of diabetes: type 1 diabetes and T2D.
There are also other forms such as gestational diabetes and rare
genetic forms such as maturity onset diabetes of the young. In
2018, an estimated 4·7 million people in the UK had diabetes(4).
This included about 3·8 million people with diagnosed diabetes
and an estimated 1 million people who were undiagnosed.
T2D accounts for about 90%of all cases of diabetes in theUK(4–6)
and occurs as a result of reduced beta-cell insulin secretion and
increased insulin resistance(7). Although several non-modifiable risk
factors such as age, family history and ethnicity are associated with
increased T2D risk, about 80–85% of an individual’s risk of develop-
ing T2D is associated with obesity(8), a modifiable risk factor.
Current UK government advice
Current UK government advice on carbohydrate intake is based
on recommendations made by Scientific Advisory Committee on
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Nutrition (SACN) following its review on carbohydrates and
health(3). The evidence considered in the SACN review on car-
bohydrates comprised studies in the general population, and
recommendations were for the UK general population.
Current UK government advice for the general population is
that approximately 50 % of total dietary energy should be
obtained from carbohydrates, mainly from starchy foods consist-
ing of high fibre or whole-grain food where possible. It is recom-
mended that average population intake of free sugars should not
exceed 5 % of total dietary energy and that adults should achieve
a daily dietary fibre intake of 30 g/d.
There are no separate recommendations on carbohydrate
intake for adults with T2D, and the advice for the general UK
population thus applies to those with T2D.
In England, the National Institute for Health and Care
Excellence has issued guidelines for the identification, diagnosis
and management of T2D including dietary advice that is in line
with UK government advice for the general population(9). The
Scottish Intercollegiate Guidelines Network has also issued
guidelines on management of diabetes including offering adults
with T2D a range of dietary options for achievingweight loss that
may also improve glycaemic control(10).
The ultimate aim of T2D management and treatment is to
reduce and maintain glycated haemoglobin (HbA1c) concentra-
tion at a value below the cut-off for the definition of T2D.
However, any reduction in HbA1c reflects an improvement in
the degree of T2D control. Improvement of blood lipids and
blood pressure is also an important treatment goal.
Management of T2D usually involves behavioural interven-
tions (including diet, physical activity, smoking cessation and
reduced alcohol intake) and/ormedications. Treatmentmay also
include bariatric surgery to reduce weight.
A reduction in energy intake is an important part of the
behavioural interventions recommended to people with T2D
who are living with overweight or obesity. The aim of reducing
energy intake is weight loss, which in turn improves glycaemic
control. Glycaemic index and glycaemic load are measures of
the post-prandial blood glucose response to foods.
Both Diabetes UK and the American Diabetes Association
emphasise tailoring advice to the individual, and both note
the lack of clear evidence for a specific dietary intake of carbo-
hydrate for those with T2D(11,12).
Purpose of review
SACN initiated this evidence review in response to a request from
PublicHealth England, for a systematic assessment of the scientific
evidence on ‘low’-carbohydrate diets, in recognition that such
diets are gaining attention and increasingly being promoted.
Methods
SACN’s Framework for the Evaluation of Evidence(2) was used as
the basis for assessing the evidence. Public Health England con-
ducted a search of key online databases: MEDLINE, Embase, the
Cochrane Library (CDSR and DARE), National Institute for
Health and Care Excellence evidence, TRIP and Google
Scholar to identify relevant English language articles published
between 1980 and 30 September 2018, using an agreed list of
search terms focusing on lower carbohydrate diets and T2D.
There was a particular interest in the following primary out-
comes: weight change (≥12 months), glycated Hb (HbA1c), a
marker of impaired glycaemic control (≥3 months), and secon-
dary outcomes: body weight (≥3 to <12 months), fasting plasma
glucose (≥3months), blood lipid profiles (≥3months) andmedi-
cation use.
SACN invited interested parties to highlight relevant evidence
which satisfied the inclusion criteria for the report through a call
for evidence from 9 February to 7 March 2018.
The report included evidence from systematic reviews (SR)
and meta-analyses (MA) and pooled analyses of randomised
controlled trials (RCT) and prospective cohort studies comparing
the impact of lower v. higher carbohydrate diets on markers and
clinical outcomes of T2D. It also included RCT published after
the most recent SR, MA and pooled analyses of RCT(2). Only
SR that included studies with a minimum duration of 3 months
and individuals with pre-diagnosed T2D (as defined in the pri-
mary RCT) when they entered the study were considered.
Two reviewers independently screened titles and abstracts of
the publications identified by the literature search and sub-
sequently assessed full-text articles. Any differences were
resolved by consensus.
For the purposes of this report, in order to enable compari-
sons of carbohydrate intake across the studies under considera-
tion, the classification proposed by Feinman et al. (2015)(13) was
adopted as the basis for categorisation of carbohydrate intake
(See Table 1).
The quality of included SR and MA was assessed by the
approach outlined in the SACN Framework for the Evaluation
of Evidence(2) and the AMSTAR 2 tool(15). Expert judgement,
based on pre-specified criteria, was used to grade the strength
of the evidence (adequate, moderate, limited, inconsistent or
insufficient) for the primary and secondary outcomes. Only out-
comes where the evidence base was graded as adequate or
moderate were used to inform recommendations.
Evidence identified
After removal of duplicates, the online database search identified
3169 abstracts which were screened for eligibility. Full texts of
nineteen potentially relevant SR with MA were retrieved and
assessed. Out of these, fifteen were excluded. Five additional
publications that met the inclusion criteria were identified by
SACN working group members. In total, nine publications met
Table 1. Categories of dietary carbohydrate intakes based on Feinman
et al. (2015)(13) and Accurso et al. (2008)(14)
Description
Amount of carbohydrate
g/d % TE (based on 2000 kcal/d)
Very low carbohydrate† 20–50 ≤10
Low carbohydrate >50–<130 >10–<26
Moderate carbohydrate 130–230 26–45
High carbohydrate >230 >45
† Also referred to as ketogenic diets.
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the criteria andwere included for data extraction, including eight
SR with MA and one network meta-analysis (See Fig. 1).
After detailed assessment, results from four SR with MA(16–19)
were used to grade the evidence and draw conclusions. This is
because they were more recent, had larger numbers of
participants and were considered to be of better quality based
on the SACN Framework for the Evaluation of Evidence(2) and
AMSTAR 2 criteria(15). Out of the thirty-six publications included
in the MA, eighteen reported outcomes in the shorter term (mini-

















Full text articles assessed for 
eligibility
n 19
Publications included in 
review
SR with MA: n 8
NMA: n 1
Studies excluded, not relevant 
based on full-text assessment
n 15
Citations excluded, not 
relevant based on title and 
abstract 
n 3150
Full text assessment of 
additional records identified 
through call for evidence 
n 13 
by WG members during 
review of evidence
n 5
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SRs with MA =4
Fig. 1. Flow diagram showing the number of publications assessed for eligibility and included in the evidence review.
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outcomes in the longer term (minimum duration of 12 months).
In this report, shorter term refers to studies or assessments that
reported at ≥3 to 6 months (since all except 1 of the time points
included in shorter-term studies or assessments did not extend
beyond 6months) and longer term refers to studies that reported
outcomes at ≥12 months.
Body weight. The evidence for lower compared with higher
carbohydrate diets on body weight was inconsistent in the
shorter term (≥3 to 6 months); there was a greater reduction
in body weight with lower compared with higher carbohydrate
diets at 3months, but this differencewas not observed between 3
and 6 months or at 6 months. There was adequate evidence for
no difference in effect between lower and higher carbohydrate
diets in reducing body weight in the longer term (≥12 months).
HbA1c. There was adequate evidence of a greater reduction in
HbA1c with lower compared with higher carbohydrate diets in
the shorter term (≥3 to 6 months). The evidence was inconsis-
tent in longer-term studies with a duration of 12 up to 24 months.
There was adequate evidence for no difference between lower
and higher carbohydrate diets on HbA1c change in longer-term
studies at 24 months.
Fasting plasma glucose. There was moderate evidence of a
greater reduction in fasting plasma glucosewith lower compared
with the higher carbohydrate diets in the shorter term (≥3 to 6
months). There was insufficient evidence to assess if there
was a difference between lower and higher carbohydrate diets
on fasting plasma glucose in the longer term (≥12 months).
Serum total cholesterol. There was moderate evidence for no
difference in effect between lower and higher carbohydrate diets
in reducing serum total cholesterol in the shorter term (≥3 to 6
months). There was adequate evidence for no difference in
effect between lower and higher carbohydrate diets in reducing
serum total cholesterol in the longer term (≥12 months).
Serum TAG. There was adequate evidence of a greater reduc-
tion in serum TAG with lower compared with higher carbohy-
drate diets in the shorter term (≥3 to 6 months). The evidence
was inconsistent in the longer term (≥12 months).
Serum LDL-cholesterol. There was adequate evidence for no
difference in effect between lower and higher carbohydrate diets
on change in serum LDL-cholesterol in the shorter term (≥3 to 6
months) and in the longer term (≥12 months).
Serum HDL-cholesterol. The evidence on lower compared
with higher carbohydrate diets on serum HDL-cholesterol was
inconsistent in the shorter term (≥3 to 6months) and longer term
(≥12 months).
Changes inmedication use. Therewasmoderate evidence of a
greater reduction in medication use with lower compared with
higher carbohydrate diets. This outcome was not assessed
according to study duration. It was not possible to assess consis-
tency in effect size.
Limitations of the evidence base
The overall quality of the evidence basewas limited by a number
of uncertainties in the data, including: variability in the definition
of a low-carbohydrate diet; smaller than prescribed differences
in reported carbohydrate intakes between lower and higher
carbohydrate diets; inherent inaccuracies in estimates of self-
reported dietary intakes and lack of information on adherence
to prescribed diets.
An important limitation was that risk of bias was high or
unclear in most of the primary RCT that were included in the
MA. This reduces the confidence that can be placed on the esti-
mates of the effects of lower carbohydrate diets on the markers
of T2D and clinical outcomes under consideration.
Another important limitation in the evidence base was that
shorter-term studies did not assess outcomes beyond 6 months
and few longer-term studies assessed outcomes beyond 12
months.
The majority of participants in the primary RCT were living
with overweight (BMI≥ 25 to <30 kg/m2) or obesity
(BMI≥ 30 kg/m2). It is not known if reported effects can be gen-
eralised to adults with a healthy weight (BMI≥ 18·5 to <25
kg/m2).
It is not known if the reported effects of lower carbohydrate
diets apply to individuals of different ethnicities since the major-
ity of primary RCT did not report ethnicity of participants and
most were conducted in populations that were predominantly
White. In those that reported ethnicity, none conducted sub-
group analyses based on ethnicity.
This report did not assess evidence on the effect of lower
carbohydrate diets in the general population without T2D. It is
not known if the reported effects of lower carbohydrate diets
in adults with T2D apply to the general adult population with-
out T2D.
Several additional gaps were identified in the evidence base:
• no trials provided information about the type of carbohydrate
consumed (e.g. wholegrain, refined grain, free sugars, fibre)
or considered how this could affect the outcomes of interest;
• the potential impact of increasing the proportions of other
macronutrients (usually fats and/or proteins) to compensate
for reduced carbohydrate intake in the lower carbohydrate
groups, or the type of macronutrient (e.g. saturated or unsatu-
rated fats; plant- or animal-based proteins), on markers and
clinical outcomes of T2D was generally not considered; and
• no trials considered clinical endpoints such as diabetes com-
plications, CVD events or mortality
Conclusions
Overall, the evidence suggests beneficial effects of lower carbo-
hydrate diets for some outcomes (HbA1c, fasting plasma glu-
cose, serum TAG) in the shorter term (up to 6 months). Since
the shorter-term assessments did not report outcomes between
6 and 12 months, it is uncertain if the suggested benefits are
maintained beyond 6 months.
Although there was no consistent evidence of reductions in
body weight with lower carbohydrate diets, it is not possible,
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from the evidence considered, to separate the effects of weight
change from effects of change in carbohydrate intake.
Lower carbohydrate diets may allow reductions in diabetes
medication, but interpretation is complicated by inconsistencies
in reporting and measurement of changes in medication use.
No differences were observed between higher and lower
carbohydrate diets on serum total or LDL-cholesterol either in
the shorter (≥3 to 6 months) or longer term (≥12 months).
Evidence on HDL-cholesterol was inconsistent in the shorter
(≥3 to 6 months) and longer term (≥12 months).
In general, there was no difference in adverse events
between lower and higher carbohydrate diets but study duration
did not extend beyond 12months in themajority of primary RCT.
Recommendations
The report states that recommendations are applicable to adults
living with T2D and overweight or obesity. There was insuffi-
cient evidence to make recommendations for adults living with
T2D without overweight or obesity. The report did not assess
evidence on the effect of lower carbohydrate diets in the general
population without T2D.
The report makes the following recommendations:
• For adults living with T2D and overweight or obesity, a lower
carbohydrate diet can be recommended by clinicians as an
effective short-term option (up to 6 months) for improving
glycaemic control and serum TAG concentrations.
• Individuals living with T2D and overweight or obesity who
choose a lower carbohydrate diet should include whole-grain
or higher fibre foods, a variety of fruits and vegetables and
limit intakes of saturated fats, reflecting current dietary advice
for the general population.
• Since the majority of individuals living with T2D have over-
weight or obesity, weight management remains the primary
goal for improving glycaemic control and reducing CVD risk.
Health professionals should support any evidence-based
dietary approach that helps individuals with T2D to achieve
long-term weight reduction.
• Adults living with T2D and overweight or obesity who change
to a lower carbohydrate diet and are taking diabetes medica-
tion may be at risk of hypoglycaemia. It is recommended that
they receive advice and support from their health care team to
manage this risk and to make adjustments to their medication
as required.
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